{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:29:28Z","timestamp":1790882968113,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1124\/mol.106.028688","type":"journal-article","created":{"date-parts":[[2006,8,23]],"date-time":"2006-08-23T03:53:26Z","timestamp":1156305206000},"page":"1822-1831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["A 46-Amino Acid Segment in Phosphodiesterase-5 GAF-B Domain Provides for High Vardenafil Potency over Sildenafil and Tadalafil and Is Involved in Phosphodiesterase-5 Dimerization"],"prefix":"10.1016","volume":"70","author":[{"given":"Mitsi A.","family":"Blount","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Zoraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengming","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel P.","family":"Bessay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie D.","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharron H.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.106.028688_REF1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0968-0004(97)01148-1","article-title":"The GAF domain: an evolutionary link between diverse phototransducing proteins","volume":"22","author":"Aravind","year":"1997","journal-title":"Trends Biochem Sci"},{"key":"10.1124\/mol.106.028688_REF2","first-page":"2164","article-title":"Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes","volume":"159","author":"Ballard","year":"1998","journal-title":"JUrol"},{"key":"10.1124\/mol.106.028688_REF3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1124\/mol.66.1.144","article-title":"Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation","volume":"66","author":"Blount","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.106.028688_REF4","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/mol.106.028688_REF5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.neuint.2004.03.016","article-title":"Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5)","volume":"45","author":"Corbin","year":"2004","journal-title":"Neurochem Int"},{"key":"10.1124\/mol.106.028688_REF6","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1124\/mol.63.6.1364","article-title":"[3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP","volume":"63","author":"Corbin","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.106.028688_REF7","doi-asserted-by":"crossref","first-page":"13729","DOI":"10.1074\/jbc.274.20.13729","article-title":"Cyclic GMP phosphodiesterase-5: target of sildenafil","volume":"274","author":"Corbin","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.106.028688_REF7a","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.ijir.3901411","article-title":"Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil [published erratum appears in Int J Impot Res 2006;18:413]","volume":"18","author":"Corbin","year":"2006","journal-title":"Int J Impot Res"},{"key":"10.1124\/mol.106.028688_REF9","unstructured":"Daugan AC-M (2000), inventor; ICOS Corporation, assignee. Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence. U.S. Patent no. 6,140,329. 2000 Oct 31."},{"key":"10.1124\/mol.106.028688_REF10","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1021\/bi00405a027","article-title":"Relationships between apparent binding energies measured in site-directed mutagenesis experiments and energetics of binding and catalysis","volume":"27","author":"Fersht","year":"1988","journal-title":"Biochemistry"},{"key":"10.1124\/mol.106.028688_REF11","doi-asserted-by":"crossref","first-page":"34613","DOI":"10.1074\/jbc.274.49.34613","article-title":"Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phospho-diesterase (PDE5)","volume":"274","author":"Fink","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.106.028688_REF12","doi-asserted-by":"crossref","first-page":"47581","DOI":"10.1074\/jbc.M206088200","article-title":"Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity","volume":"277","author":"Francis","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.106.028688_REF13","first-page":"1","article-title":"Cyclic nucleotide phosphodiesterases: relating structure and function","volume":"65","author":"Francis","year":"2001","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"10.1124\/mol.106.028688_REF14","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/mol.106.028688_REF15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0301-4622(94)00006-9","article-title":"Gibbs free energy of adsorption for biomolecules in ion-exchange systems","volume":"52","author":"Gerstner","year":"1994","journal-title":"Biophys Chem"},{"key":"10.1124\/mol.106.028688_REF16","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1074\/jbc.M511468200","article-title":"cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11","volume":"281","author":"Gross-Langenhoff","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.106.028688_REF17","first-page":"L931","article-title":"Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity","volume":"275","author":"Hanson","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1124\/mol.106.028688_REF18","doi-asserted-by":"crossref","first-page":"13095","DOI":"10.1074\/jbc.M311556200","article-title":"Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity","volume":"279","author":"Huai","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.106.028688_REF19","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1046\/j.1464-410X.1997.00206.x","article-title":"Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro","volume":"79","author":"Jeremy","year":"1997","journal-title":"Br J Urol"},{"key":"10.1124\/mol.106.028688_REF20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0302-2838(03)00153-2","article-title":"DA-8159, a new PDE5 Iihibitor, induces penile erection in conscious and acute spinal cord injured rabbits","volume":"43","author":"Kang","year":"2003","journal-title":"Eur Urol"},{"key":"10.1124\/mol.106.028688_REF21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1517\/14656566.5.4.923","article-title":"Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction","volume":"5","author":"Kendirci","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/mol.106.028688_REF22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1124\/mi.2.5.317","article-title":"GAF domains: two-billion-year-old molecular switches that bind cyclic nucleotides","volume":"2","author":"Martinez","year":"2002","journal-title":"Mol Interv"},{"key":"10.1124\/mol.106.028688_REF23","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1073\/pnas.0409913102","article-title":"Crystal structure of the tandem GAF domains from a cyanobacterial adenylyl cyclase: modes of ligand binding and dimerization","volume":"102","author":"Martinez","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.106.028688_REF24","doi-asserted-by":"crossref","first-page":"30671","DOI":"10.1074\/jbc.270.51.30671","article-title":"An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase","volume":"270","author":"McAllister-Lucas","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.106.028688_REF25","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2741\/1617","article-title":"NO-sensitive guanylyl cyclase and NO-induced feedback inhibition in cGMP signaling","volume":"10","author":"Mullershausen","year":"2005","journal-title":"Front Biosci"},{"key":"10.1124\/mol.106.028688_REF26","doi-asserted-by":"crossref","first-page":"30338","DOI":"10.1074\/jbc.M312687200","article-title":"The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases","volume":"279","author":"Richter","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.106.028688_REF27","first-page":"60","article-title":"Tadalafil Lilly ICOS","volume":"4","author":"Rotella","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/mol.106.028688_REF28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1161\/01.RES.0000087541.15600.2B","article-title":"Cyclic GMP phosphodiesterases and regulation of smooth muscle function","volume":"93","author":"Rybalkin","year":"2003","journal-title":"Circ Res"},{"key":"10.1124\/mol.106.028688_REF29","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1161\/01.CIR.0000074226.20466.B1","article-title":"Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension","volume":"107","author":"Sebkhi","year":"2003","journal-title":"Circulation"},{"key":"10.1124\/mol.106.028688_REF30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0926-6585(66)90333-5","article-title":"Determination of molecular weights and frictional ratios of proteins in impure systems by use of gel filtration and density gradient centrifugation. Application to crude preparations of sulfite and hydroxylamine reductases","volume":"112","author":"Siegel","year":"1966","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/mol.106.028688_REF31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.cellsig.2003.11.004","article-title":"The cGMP-binding, cGMP-specific phosphodiesterase (PDE5): intestinal cell expression, regulation and role in fluid secretion","volume":"16","author":"Sopory","year":"2004","journal-title":"Cell Signal"},{"key":"10.1124\/mol.106.028688_REF32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature01914","article-title":"Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules","volume":"425","author":"Sung","year":"2003","journal-title":"Nature (Lond)"},{"key":"10.1124\/mol.106.028688_REF33","first-page":"45","article-title":"Partial mapping of cyclic nucleotide sites and studies of regulatory mechanisms of phosphodiesterases using cyclic nucleotide analogues","volume":"25","author":"Thomas","year":"1992","journal-title":"Adv Second Messenger Phosphoprotein Res"},{"key":"10.1124\/mol.106.028688_REF34","doi-asserted-by":"crossref","first-page":"14964","DOI":"10.1016\/S0021-9258(18)77210-4","article-title":"Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase","volume":"265","author":"Thomas","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.106.028688_REF35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0026-895X(24)26391-4","article-title":"Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds","volume":"56","author":"Turko","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.106.028688_REF36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1042\/bj3290505","article-title":"Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation","volume":"329","author":"Turko","year":"1998","journal-title":"Biochem J"},{"key":"10.1124\/mol.106.028688_REF37","first-page":"H448","article-title":"ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells","volume":"274","author":"Wyatt","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1124\/mol.106.028688_REF38","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1073\/pnas.79.12.3702","article-title":"Reciprocal effects of an inhibitory factor on catalytic activity and noncatalytic cGMP binding sites of rod phosphodiesterase","volume":"79","author":"Yamazaki","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.106.028688_REF39","doi-asserted-by":"crossref","first-page":"12051","DOI":"10.1074\/jbc.M413611200","article-title":"Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation","volume":"280","author":"Zoraghi","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.106.028688_REF40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/mol.65.2.267","article-title":"Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteins","volume":"65","author":"Zoraghi","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.106.028688_REF41","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1074\/jbc.M510372200","article-title":"Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity","volume":"281","author":"Zoraghi","year":"2006","journal-title":"J Biol Chem"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24042366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24042366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.106.028688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:35:39Z","timestamp":1739964939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24042366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0026895X24042366"],"URL":"https:\/\/doi.org\/10.1124\/mol.106.028688","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 46-Amino Acid Segment in Phosphodiesterase-5 GAF-B Domain Provides for High Vardenafil Potency over Sildenafil and Tadalafil and Is Involved in Phosphodiesterase-5 Dimerization","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.106.028688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2006 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}